The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by RFA-TR-24-023.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,195,528 in first-year total cost, median $311,189.
Most frequent study sections
- Special Emphasis Panel[ZTR1 RD-1 (01)]4
Most frequent institutions
- DUKE UNIVERSITY1
- MYOGENE BIO, LLC1
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
- UNIVERSITY OF TEXAS AT AUSTIN1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome1R21TR005157-01 | SABA, JULIE D | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $463,150 | ZTR1 |
| 2024 | Effective treatment of cystinuria with a novel engineered cyst(e)ine-degrading human enzyme therapy1R21TR005156-01 | GEORGIOU, GEORGE GEORGIOU | UNIVERSITY OF TEXAS AT AUSTIN, TX | $437,761 | ZTR1 |
| 2024 | Triacetin Treatment for Propionic Acidemia by Rebalancing the Acetyl-CoA/Propionyl-CoA Metabolism1R21TR005163-01 | CHEN, XIAOXIN LUKEZHANG, GUOFANG | DUKE UNIVERSITY, NC | $184,617 | ZTR1 |
| 2024 | Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy1R21TR005162-01 | YOUNG, COURTNEY S | MYOGENE BIO, LLC, CA | $110,000 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.